Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:MYNZNASDAQ:OCUPNASDAQ:ONCY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$667K0.6763,976 shs1,159 shsMYNZMainz Biomed$0.93-2.1%$1.01$0.85▼$6.00N/A0.2483,379 shs22,575 shsOCUPOcuphire Pharma$1.74$2.20$1.70▼$6.60$43.17M0.33219,407 shs92,405 shsONCYOncolytics Biotech$1.04-3.7%$1.07$0.88▼$3.39$78.44M1.93388,070 shs178,056 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%-9.17%-4.22%-10.80%-99.45%MYNZMainz Biomed-3.76%-11.31%-6.88%-12.97%-82.69%OCUPOcuphire Pharma0.00%-6.45%-9.84%-37.18%-71.19%ONCYOncolytics Biotech-3.70%-7.96%0.00%-11.11%-9.57%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics1.801 of 5 stars3.00.00.04.82.60.00.6MYNZMainz Biomed2.1743 of 5 stars3.34.00.00.03.10.00.0OCUPOcuphire Pharma2.3439 of 5 stars3.52.00.00.02.51.71.3ONCYOncolytics Biotech0.9287 of 5 stars3.53.00.00.01.30.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,569.72% UpsideMYNZMainz Biomed2.50Moderate Buy$6.00544.33% UpsideOCUPOcuphire Pharma3.00Buy$19.00991.95% UpsideONCYOncolytics Biotech3.00Buy$4.00284.62% UpsideCurrent Analyst RatingsLatest MYNZ, OCUP, BLPH, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MYNZMainz BiomedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/20/2024OCUPOcuphire PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.003/6/2024MYNZMainz BiomedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/19/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AMYNZMainz Biomed$900KN/AN/AN/A$0.27 per shareN/AOCUPOcuphire Pharma$19.05M2.27N/AN/A$2.20 per share0.79ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)MYNZMainz Biomed-$26.30M-$1.64N/A∞N/A-2,934.82%-488.05%-145.77%5/21/2024 (Estimated)OCUPOcuphire Pharma-$9.99M-$0.48N/AN/AN/A-52.42%-22.30%-20.27%5/20/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)Latest MYNZ, OCUP, BLPH, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023OCUPOcuphire Pharma-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 million3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96MYNZMainz Biomed0.360.970.91OCUPOcuphire PharmaN/A13.3513.35ONCYOncolytics BiotechN/A9.019.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%MYNZMainz BiomedN/AOCUPOcuphire Pharma14.97%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%MYNZMainz BiomedN/AOCUPOcuphire Pharma8.70%ONCYOncolytics Biotech0.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableMYNZMainz Biomed65N/AN/ANot OptionableOCUPOcuphire Pharma1424.81 million22.65 millionOptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableMYNZ, OCUP, BLPH, and ONCY HeadlinesSourceHeadlineBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Casestheglobeandmail.com - April 13 at 12:42 AMUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fightfinanznachrichten.de - April 11 at 2:15 PMOncolytics seeking FDA meeting to discuss registration-enabling studymsn.com - April 11 at 2:15 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAprnewswire.com - April 11 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond Jamesmarketbeat.com - April 4 at 2:58 PMOncolytics Biotech (NASDAQ:ONCY) Trading Down 1.9%marketbeat.com - March 21 at 12:58 AMUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergencyfinanznachrichten.de - March 14 at 9:24 AMBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trialsmarkets.businessinsider.com - March 11 at 7:59 AMOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 10 at 10:18 AMBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trialsmarkets.businessinsider.com - March 8 at 8:46 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsfinanznachrichten.de - March 8 at 10:45 AMOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsprnewswire.com - March 7 at 4:01 PMOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANprnewswire.com - March 5 at 7:00 AMOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conferenceprnewswire.com - February 28 at 7:00 AMHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situationfinance.yahoo.com - February 15 at 3:44 PMOncolytics Biotech Incbaystreet.ca - February 15 at 10:44 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsnewsfilecorp.com - February 15 at 8:00 AMOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 1:27 PMOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinance.yahoo.com - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortprnewswire.com - February 14 at 7:00 AMOutlook stock rallies on private placement, FDA study agreementmsn.com - January 23 at 11:32 AMOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinanznachrichten.de - January 9 at 7:50 AMOncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinance.yahoo.com - January 9 at 7:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Mainz BiomedNASDAQ:MYNZMainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.